Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Gennaro Gadaleta Caldarola"'
Autor:
Antonello Pinto, Chiara Guarini, Marianna Giampaglia, Valeria Sanna, Assunta Melaccio, Laura Lanotte, Anna Natalizia Santoro, Francesca Pini, Antonio Cusmai, Francesco Giuliani, Gennaro Gadaleta-Caldarola, Palma Fedele
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1146 (2024)
The advent of immunotherapy and antibody–drug conjugates (ADCs) have revolutionized breast cancer treatment, offering new hope to patients. However, challenges, such as resistance and limited efficacy in certain cases, remain. Recently, the combina
Externí odkaz:
https://doaj.org/article/7a271d13ab684c7ca0b0fb20eae97d14
Autor:
Gennaro Gadaleta-Caldarola, Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Arianna Gadaleta-Caldarola, Stefania Infusino, Antonio Cusmai, Claudia Citrigno, Gennaro Palmiotti
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7925-7931 (2022)
Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemig
Externí odkaz:
https://doaj.org/article/4fa626ba992f49b19c039aaaba1e5f5f
Autor:
Gennaro Gadaleta-Caldarola, Laura Lanotte, Stefania Infusino, Arianna Gadaleta-Caldarola, Francesca Matilde Schipilliti, Claudia Citrigno, Cataldo Petrarota, Antonio Cusmai, Alessandro Rizzo
Publikováno v:
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100775- (2023)
Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research design and methods: Herein, we
Externí odkaz:
https://doaj.org/article/d4e1879ceb08478b8f850e8b44cd69ae
Autor:
Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3393-3402 (2021)
Ampullary carcinomas (ACs) represent a rare entity, accounting for approximately 0.2% of all gastrointestinal solid tumors and 20% of all periampullary cancers (PACs). Unfortunately, few data are available regarding the optimal therapeutic strategy f
Externí odkaz:
https://doaj.org/article/a3ac9ac9a7c440cb99b9c5445e4faf79
Autor:
Alessandro Rizzo MD, Antonio Cusmai MD, Raffaella Massafra PhD, Samantha Bove PhD, Maria Colomba Comes PhD, Annarita Fanizzi PhD, Gennaro Gadaleta-Caldarola MD, Donato Oreste MD, Alfredo Zito MD, Francesco Giotta MD, Vito Lorusso MD, Gennaro Palmiotti MD
Publikováno v:
Cancer Control, Vol 29 (2022)
Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2
Externí odkaz:
https://doaj.org/article/360c03889f5c4df8bfe1bc8d24c80f02
Autor:
Rosa Divella, Graziella Marino, Stefania Infusino, Laura Lanotte, Gaia Gadaleta-Caldarola, Gennaro Gadaleta-Caldarola
Publikováno v:
Nutrients, Vol 15, Iss 7, p 1667 (2023)
A healthy diet and an active lifestyle are both effective ways to prevent, manage, and treat many diseases, including cancer. A healthy, well-balanced diet not only ensures that the body gets the right amount of nutrients to meet its needs, but it al
Externí odkaz:
https://doaj.org/article/7411b20de5084008870a2a6f4aed028d
Autor:
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici, Giovanni Brandi
Publikováno v:
Medicina, Vol 58, Iss 11, p 1543 (2022)
Objectives: The ABC-06 and the NIFTY trials recently established the role of second-line chemotherapy (2L) in patients with advanced biliary tract cancer (BTC). Our real-world study aimed to explore 2L in BTC patients aged ≥ 70 years old and to com
Externí odkaz:
https://doaj.org/article/21706d9457d3468996d4a95259512694
Autor:
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Publikováno v:
Cells, Vol 11, Iss 12, p 1857 (2022)
Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant
Externí odkaz:
https://doaj.org/article/1d10e54901184395b763dfcdee2f06db
Publikováno v:
Medicina, Vol 58, Iss 5, p 600 (2022)
Immunotherapy has revolutionized previous triple-negative breast cancer (TNBC) treatment algorithms, prompting researchers and clinicians to consider the expansion of the role of immunotherapy in other settings, including the earlier stage of the dis
Externí odkaz:
https://doaj.org/article/710760f412234130b69dfa9dcd1ba341
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 16:333-339
Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Recent years have seen the emergence of novel systemic treatments for HCC patients, including immune ch